lemzoparlimab + dexamethasone

Lemzoparlimab + dexamethasone is an investigational combination therapy used primarily in clinical trials for the treatment of relapsed or refractory multiple myeloma. Lemzoparlimab is a humanized monoclonal antibody targeting CD47, thereby blocking the CD47-SIRPα interaction and promoting phagocytosis of tumor cells. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties, often used as a supportive or combination agent in oncology. Lemzoparlimab is typically administered intravenously, while dexamethasone is administered orally or intravenously. The combination has been tested alone and alongside other anti-myeloma regimens in early-phase clinical studies[1][4][5][9].